Approvals· July 27, 2026 · 18 min read
Topic
Sickle Cell Disease
Sickle cell therapies, gene editing access, CMS CGT Access Model, Medicaid outcomes-based contracts, and rare-disease access.
Sickle cell therapies, gene editing access, CMS CGT Access Model, Medicaid outcomes-based contracts, and rare-disease access.